Hypoxia Preconditioning Promotes Survival And Clonogenic Capacity Of Human Umbilical Cord Blood Mesenchymal Stem Cells
Authors
Abstract:
Background: In recent decade, human umbilical cord blood derived mesenchymal stem cells (hUCB-MSCs) provide enormous potential for appropriate cell therapy, but they have limited growth potential and cease to proliferate due to cellular senescence, so providing a strategy for increasing the stem cell survival is necessary. Methods: In this investigation, MSCs characterized by flow cytometry were isolated from umbilical cord blood. Hypoxia preconditioning (HPC) was induced in a water-saturated gas mixture of 2.5% O2 and 5% CO2 for 15 min and then reoxygenation at 21% O2 for 30 min at 37 °C. Subsequently, hypoxia preconditioned hUCB-MSCs were exposed to 2.5% O2 and 5% CO2 for 24, 48 and 72 hr (HPC + hypoxia groups). We examined the proliferation capacity of hUCB-MSCs after HPC in comparison with normoxia status, and we determined the best duration time of being under hypoxia (24, 48 or 72 hr of hypoxia). In order to assess the role of HPC on the expression of surface markers, cells were analyzed by flow cytometry. Proliferation of cells was evaluated using MTT assay, and doubling time and colony-forming unit-fibroblast (CFU-F) was calculated in each group. Results: The MTT results showed that cell viability of HPC-UCB-MSCs significantly increased in comparison with UCB-MSCs under normoxia condition. Our study revealed that HPC reduces the doubling time of UCB-MSCs remarkably after passaging 48 hours of hypoxia. Our results proved that HPC can significantly increase the CFU-F colony numbers of hUCB-MSCs without any alteration on cell surface marker expression. Conclusion: Our results suggested that HPC of umbilical cord blood derived mesenchymal stem cells along with induction of hypoxia can provide a suitable culture condition for rapid proliferation of mesenchymal stem cells with no effect on their immunophenotype features and it could be a potential therapeutic option for increasing the capability of MSCs.
similar resources
Mild hypoxia and human bone marrow mesenchymal stem cells synergistically enhance expansion and homing capacity of human cord blood CD34+ stem cells
Objective(s): Cord blood (CB) is known as a valuable source of hematopoietic stem cells (HSC). Identifying strategies that enhance expansion and maintain engraftment and homing capacity of HSCs can improve transplant efficiency. In this study, we examined different culture conditions on ex vivo expansion and homing capacity of CB-HSCs. Materials and Methods: In this study, 4-5 different units o...
full textIn-vitro Differentiation of Human Umbilical Cord Wharton’s Jelly Mesenchymal Stem Cells to Insulin-Producing Cells
Background & Objective: Diabetes is a major chronic metabolic disease in the world. Islet transplantation is a way to treat diabetes. Unfortunately, this method is restricted due to graft rejection and lack of donor islets. Mesenchymal Stem Cells (MSCS) have the ability to differentiate into Insulin-Producing Cells (IPCs). In this study, Human Umbilical Mesenchymal Stem Cells (HUMSCS) were in...
full textStudy of telomerase activity, proliferation and differentiation characteristics in umbilical cord blood mesenchymal stem cells
In recent years, considerable advances have been made in the field of regenerative medicine. Unlikeembryonic stem cells, which pose the problems of ethical concerns and cause severe immunological reactions as well as neoplasma formation after transplantation, umbilical cord blood is a primitive source ofmesenchymal stem cells that covers the benefits of both embryonic and adult stem cells. It h...
full textP 82: The Transplantation of Human Umbilical Cord Mesenchymal Stem Cells in Neonatal Strokes
Brain injuries that caused by strokes (result of intra partum ischemia) are a frequent cause of prenatal mortality and morbidity with limited therapeutic options. Transplanting human mesenchymal stem cells (hmscs) indicates improvement in hypoxic Ischemic brain injury (HIBD) by secretion growth factor stimulating repair processes (Hmscs) known as multi potent cells which isolated from bone marr...
full textCXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas.
Mesenchymal stem cells (MSCs) can be used as a delivery vehicle for gene therapy against brain tumors, because these cells have a migratory capacity toward glioma cells. Soluble factors including chemokines or growth factors expressed and released by glioma cells mediate the tropism of MSCs for gliomas. Among them, stromal cell-derived factor-1α (SDF-1α) has been identified as a key molecule re...
full textA New Two Step Induction Protocol for Neural Differentiation of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells
Background: In this study, we examined a new two step induction protocol for improving the differentiation of human umbilical cord blood-derived mesenchymal stem cells into neural progenitor cells. Materials and Methods: Human umbilical cord blood-derived mesenchymal stem cells were first cultured in Dulbecco’s modified eagle medium supplemented with 10% fetal bovine serum in a humidified incu...
full textMy Resources
Journal title
volume 10 issue None
pages 43- 49
publication date 2018-06
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023